CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance
journal contribution
posted on 2014-05-01, 00:00authored byJ Ni, P J Cozzi, J L Hao, J Beretov, L Chang, Wei DuanWei Duan, Sarah ShigdarSarah Shigdar, W J Delprado, P H Graham, J Bucci, J H Kearsley, Y Li
Prostate cancer (CaP) is the second leading malignancy in older men in Western countries. The role of CD44 variant 6 (CD44v6) in CaP progression and therapeutic resistance is still uncertain. Here, we investigated the roles of CD44v6 in CaP metastasis and chemo/radioresistance. Expression of CD44v6 in metastatic CaP cell lines, human primary CaP tissues and lymph node metastases was assessed using immunofluorescence and immunohistochemistry, respectively.